Clinical Trial Detail

NCT ID NCT01892046
Title Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Esanex Inc.
Indications

lung non-small cell carcinoma

lung small cell carcinoma

Therapies

Carboplatin

SNX-5422

Paclitaxel

Age Groups: adult

No variant requirements are available.